E.U. investigates pharma

Koroneos, George
January 2009
Pharmaceutical Representative;Jan2009, Vol. 39 Issue 1, p9
The article focuses on the preliminary report of the European Union on anti-competitive issues in the pharmaceutical industry. The report highlights the reasons why pharmaceutical companies are using a variety of techniques to delay generic firms from releasing inexpensive versions of their drugs. The report also focuses on the techniques that are legal and accepted in the U.S., including patenting, creating a patent thicket, and enforcing patents.


Related Articles

  • European Drug Industry Faces Antitrust Bust on Generics. O'Donnell, Peter // BioWorld International;1/23/2008, Vol. 13 Issue 4, p3 

    The article reports on the launch by the European Union (EU) of an in-depth antitrust investigation of the research-based pharmaceutical sector, in response to suspicions of artificial impediments to the entry of generic products. According to an EU statement, the inquiry is a response to...

  • Translation requirements for generics in the EU. Safar, Libor // MultiLingual;Sep2013, Vol. 24 Issue 6, p44 

    The article offers information on the requirements of translation of generic medicines in European Union countries. It mentions that as generics differ in inactive ingredients (excipients), such as colorings, appearance and packaging, and they should have the same authorization as the patented...

  • Legal And Regulatory Update.  // Journal of Commercial Biotechnology;Apr2010, Vol. 16 Issue 2, p174 

    The article presents updates related to patent regulations of the European Union (EU). In its final report on the Pharmaceutical Sector Inquiry, the European Commission expressed its concerns regarding patent settlement agreements between originator and generic companies, and the report stated...

  • FILLING THE PHARMA PIPELINE.  // Chemistry in Australia;Dec2011, Vol. 78 Issue 11, p9 

    The article reveals that a number of blockbuster patents will expire and generic pharmaceuticals will win market share from the originator pharmaceutical companies in Australia in 2012.

  • Patent Losses To Create Big Opportunities.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p65 

    The article presents the EvaluatePharma report which highlights the challenges that confront the innovator drug industry and the opportunities awaiting the generics drug sector, and shows that 13 blockbuster drugs will lose patent protection in 2013 in the U.S.

  • Branded drug companies' future pain spells big gains for generic drug makers. West, Diane // Drug Store News;03/04/2002, Vol. 24 Issue 3, p28 

    Reports on the business opportunity of generic drug makers from brand name prescription drugs' patent protection loss by 2005, according to the report, 'The Generics Industry in 2005: A New Threat to Pharma.' One tactic of generic makers to stay on top; Cost of going after high-ticket drugs;...

  • Patents hold no guarantee in new generics marketplace. Kirsche, Michelle L. // Drug Store News;11/17/2003, Vol. 25 Issue 16, p26 

    Reports that patents hold no guarantee as generic drugs take a larger share of the pharmaceutical industry. Major branded drugs that lost patent protection in 2002; List of top 10 generics companies by prescription; Advantages of early patent legal challenges; Campaign to reduce regulatory...

  • Pharma patent settlements in EU continue to rise.  // PharmacoEconomics & Outcomes News;Dec2013, Issue 693, p10 

    The article reports on the findings of a survey by the European Commission which shows an increase in the number of patent settlement agreements between originator and generic companies in 2012 which has reached 1883, up 120 in 2011.

  • Betting on biogenerics. Dove, Alan // Nature Biotechnology;Feb2001, Vol. 19 Issue 2, p117 

    Focuses on the decision taken by the pharmaceutical industry to manufacture own versions of generic drugs. Reason for the industry's decision; Scope of the drug manufacturing business in the global market; Steps to be taken by manufacturers to produce generic drugs similar to branded drugs;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics